Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice
Authors:
- 6 January 2015
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 20 (11) , 1329-1338
Abstract
The 12/15-lipoxygenase (12/15LO) enzyme is widely distributed within the central nervous system. Previous work showed that this protein is upregulated in Alzheimer’s disease (AD), and plays an active role in the development of brain amyloidosis in amyloid beta (Aβ)-precursor protein transgenic mice (Tg2576). In the present paper, we studied the effect of its pharmacologic inhibition on the AD-like phenotype of a mouse model with plaques and tangles, the triple-transgenic mice. Compared with mice receiving placebo, the group treated with PD146176, a specific 12/15LO inhibitor, manifested a significant improvement of their memory deficits. The same animals had a significant reduction in Aβ levels and deposition, which was secondary to a decrease in the β-secretase pathway. In addition, while total tau-soluble levels were unchanged for both groups, PD146176-treated mice had a significant reduction in its phosphorylation state and insoluble fraction, which specifically associated with decrease in stress-activated protein kinase/c-Jun N-terminal kinase activity. In vitro study showed that the effect on tau and Aβ were independent from each other. These data establish a functional role for 12/15LO in the pathogenesis of the full spectrum of the AD-like phenotype and represent the successful completion of the initial step for the preclinical development of 12/15LO inhibitors as novel therapeutic agents for AD.Keywords
This publication has 31 references indexed in Scilit:
- RETRACTED: Transcriptional regulation of βsecretase‐1 by 12/15‐lipoxygenase results in enhanced amyloidogenesis and cognitive impairmentsAnnals of Neurology, 2011
- Post-translational modifications of tau protein: Implications for Alzheimer's diseaseNeurochemistry International, 2011
- 5‐lipoxygenase as an endogenous modulator of amyloid beta formation in vivoAnnals of Neurology, 2010
- Blocking Aβ42Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between Aβ and Tau PathologyJournal of Neuroscience, 2008
- A role for 12/15 lipoxygenase in the amyloid β precursor protein metabolismJournal of Neurochemistry, 2007
- Absence of 12/15 Lipoxygenase Reduces Brain Oxidative Stress in Apolipoprotein E-Deficient MiceThe American Journal of Pathology, 2005
- Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by β-amyloid peptideCell Death & Differentiation, 2004
- Alterations in Glucose Metabolism Induce Hypothermia Leading to Tau Hyperphosphorylation through Differential Inhibition of Kinase and Phosphatase Activities: Implications for Alzheimer's DiseaseJournal of Neuroscience, 2004
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and TanglesNeuron, 2003
- Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass SpectrometryJournal of Neurochemistry, 2000